A seven-day, extended-release version of buprenorphine — a treatment for opioid use disorder (OUD) that can reduce opioid use and overdose deaths — is safe and effective for people with OUD ...
BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this ...
Extended-release 7-day injectable buprenorphine was safe and tolerable for most patients who had minimal-to-mild opioid withdrawal, a nonrandomized trial found. Among 100 adult patients with ...
Injectable, extended-release buprenorphine was deemed safe for patients experiencing minimal to mild opioid withdrawal (COWS scores 4-7), making the drug a viable and safe treatment option, according ...
Spark Biomedical is joined by the Battelle Memorial Institute and Hazelden Betty Ford Foundation to begin pioneering an AI-powered, wearable, closed-loop neurostimulation system to improve opioid ...
Length of treatment and neurobehavioral scores did not significantly differ between infants with prenatal opioid exposure randomized to either clonidine or morphine, researchers found. Among infants ...
6d
Spokane's Deaconess Hospital starts program to combat drug withdrawal with long-lasting medication
A pilot program from MultiCare Deaconess Hospital now provides long lasting opioid withdrawal medication. The injectable buprenorphine will provide a much more stable basis for patients to ...
Naloxone has long been hailed as a life-saving drug in the face of the opioid epidemic. But its capacity to save someone from an overdose can be limited by the potency of the opioid — a person revived ...
More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results